|
Ixico PLC - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Signs two new commercial contracts worth approximately £1.3 million in total. First contract covers around three and a half years, with Ixico providing trial management and imaging analysis for a phase 1 study by ‘a major pharmaceutical company’ on Alzheimer’s disease. The second, under which Ixico will facilitate imaging data collection for a phase 1b trial to support surgical planning in Friedrich’s ataxia, covers six years and is ‘with a US-based biotech’. ‘This positive commercial momentum continues IXICO’s successful execution of its ’Innovate, Lead, Scale’ strategy to drive global expansion and growth,’ Ixico says. Chief Executive Bram Goorden comments: ‘The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space. The two deals hit different key elements of our strategy, respectively supporting Alzheimer’s as a core indication, and maintaining our leadership position in the rare [central nervous system] disease space.’ Current stock price: 12.02 pence 12-month change: up 69% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
